The closing price of Adaptive Biotechnologies Corp (NASDAQ: ADPT) was $2.58 for the day, down -5.49% from the previous closing price of $2.73. In other words, the price has decreased by -$0.1500 from its previous closing price. On the day, 1321889 shares were traded.
Ratios:
Our analysis of ADPT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.66. In the meantime, Its Debt-to-Equity ratio is 0.74 whereas as Long-Term Debt/Eq ratio is at 0.71.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $15.
Piper Sandler Upgraded its Neutral to Overweight on December 21, 2022, whereas the target price for the stock was revised from $7.50 to $14.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 05 ’24 when ROBINS CHAD M sold 48,673 shares for $3.43 per share. The transaction valued at 167,007 led to the insider holds 2,576,701 shares of the business.
RUBINSTEIN JULIE sold 39,070 shares of ADPT for $135,764 on Mar 05 ’24. The President now owns 472,754 shares after completing the transaction at $3.47 per share. On Mar 05 ’24, another insider, BENZENO SHARON, who serves as the Chief Commercial Ofc Imm Med of the company, sold 29,390 shares for $3.44 each. As a result, the insider received 100,994 and left with 327,415 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 374.34M and an Enterprise Value of 126.71M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.20 while its Price-to-Book (P/B) ratio in mrq is 1.21. Its current Enterprise Value per Revenue stands at 0.74 whereas that against EBITDA is -0.67.
Stock Price History:
Over the past 52 weeks, ADPT has reached a high of $9.08, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is 3.5856, while the 200-Day Moving Average is calculated to be 5.0502.
Shares Statistics:
ADPT traded an average of 1.49M shares per day over the past three months and 1.92M shares per day over the past ten days. A total of 145.08M shares are outstanding, with a floating share count of 138.51M. Insiders hold about 4.54% of the company’s shares, while institutions hold 95.41% stake in the company. Shares short for ADPT as of Mar 15, 2024 were 8.46M with a Short Ratio of 5.66, compared to 9.19M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.83% and a Short% of Float of 7.48%.
Earnings Estimates
The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.37, while EPS last year was -$0.4. The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.31 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.21 and -$1.37 for the fiscal current year, implying an average EPS of -$1.3. EPS for the following year is -$1.04, with 7 analysts recommending between -$0.65 and -$1.29.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $42.2M to a low estimate of $34.8M. As of the current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $37.65M, an estimated increase of 3.00% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $185.1M, while the lowest revenue estimate was $170M, resulting in an average revenue estimate of $175.82M. In the same quarter a year ago, actual revenue was $170.28M, up 3.30% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $220.94M in the next fiscal year. The high estimate is $256.4M and the low estimate is $195.5M. The average revenue growth estimate for next year is up 25.70% from the average revenue estimate for this year.
